Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO

 
• By Ian Schofield

With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.

Reducing costs
Greater use of biosimilars, particularly in cancer, can save on healthcare costs

More from Biosimilars

More from Biosimilars & Generics